Professor Rohit Loomba played a pivotal role in a comprehensive network meta-analysis evaluating the efficacy of pharmacological therapies for fibrosis regression and MASH resolution. Published in Hepatology, this study analyzed 29 randomized controlled trials (RCTs) involving 9,324 patients, providing a comparative rank-order assessment of late-phase therapies for MASH.
Conducted alongside Matheus Souza, Lubna Al-Sharif, Vanio L. J. Antunes, Daniel Q. Huang, and others, this research identified pegozafermin, cilofexor + firsocostat, and cilofexor + selonsertib as the most effective interventions for fibrosis regression, while pegozafermin, survodutide, and tirzepatide ranked highest for MASH resolution without worsening fibrosis. Other notable agents, including obeticholic acid, resmetirom, semaglutide, pioglitazone, and denifanstat, also showed significant benefits.
Professor Loomba’s expertise in hepatology and metabolic liver diseases was instrumental in data interpretation and clinical impact analysis, helping to establish a data-driven approach for guiding treatment decisions and clinical trial designs in MASH.
For more information: https://lnkd.in/ea3G8JZF
